Study to Evaluate KOS-1584 in Patients With Advanced or Metastatic Stage IIIB/IV Non-Small Cell Lung Cancer (NSCLC)

Completed · Phase 2

Conditions studied: Non-Small Cell Lung Cancer

In brief

The purpose of this study is to determine the Objective Response Rate of KOS-1584, as a single agent in patients with stage IIIB/IV NSCLC whose disease has progressed following initial chemotherapy.

Key facts

Study ID

NCT00651508

Run by

Bristol-Myers Squibb

People needed

1

Starts

2008-04-01

Expected to finish

2008-10-01

Last updated by the study team

2016-05-17

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Histologically or cytologically proven NSCLC, Stage IIIB or Stage IV.
• Eligible patients must have received only one prior chemotherapy regime for Stage IIIB/IV NSCLC.
• Good performance status.

You may not qualify if…

• Prior treatment with an epothilone.
• Known central nervous system (CNS) metastases.
• Any chemotherapy, radiation therapy or immunotherapy or any investigational agent (therapeutic or diagnostic) within 3 weeks prior to first study drug administration.

Where it is running

• Consultants In Blood Disorders & Cancer — Louisville, Kentucky, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.